Mercy in the face of agony or commercialisation of the end of life? How should the EU respond to the varying legal stances across Member States concerning assisted suicide and the subsequent potential for "death tourism"?
The economic costs of burn-out and other work-related health problems – How can the EU and its Member States support employers in their efforts to reduce long-term absence and early retirement?
Meeting the ever-increasing shortage of organs worldwide: How can the EU improve cross-border organ exchange while ensuring the efficiency and safety of transplantation systems?
Facing an ageing society and a rise in the prevalence of chronic diseases, costs for European health care systems are expected to increase drastically over the next few decades. What steps of promotion, prevention and early detection can the EU take to support Member States in their actions against chronic diseases?
As antimicrobial resistance (AMR) is one of the major threats to public health worldwide, which further steps should the EU prioritise in the field of veterinary medicine and medicated feed, after the expiration of the European Commission’s “2011-2016 action plan against the rising threats from AMR”?
Following on from Jamie Oliver’s Sugar Manifesto, the UK recently announced the introduction of a tax on sugary drinks. Should the EU and its Member States increase their efforts to control the markets of sugary drinks and other unhealthy food products in order to combat childhood obesity?
Providing consistent laboratory services in structurally weak areas: How can EU Member States ensure effective medical infrastructure without sacrificing the quality of laboratory diagnostics and patient safety?
Medical care moving towards the digital cloud: How can the EU and its Member States utilise the benefits of telemedicine and eHealth whilst safeguarding patients' data across Europe?
Shifting structures in the pharmaceutical market: as patents expire and generics enter the market, to what extent should the EU protect pharmaceutical companies’ intellectual property while ensuring fair prices for patients?